CP
XENE icon

Caligan Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Caligan Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81M Buy
1,393,027
+843,362
+153% +$38.9M 5.39% 5
2025
Q4 		$24.6M Buy
549,665
+105,100
+24% +$4.41M 2.03% 13
2025
Q3 		$17.8M Buy
+444,565
New +$15.7M 2.34% 11

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caligan Partners's XENE Position: Q1 2026 in Review

Caligan Partners increased its Xenon Pharmaceuticals (XENE) stake by 153% in Q1 2026, buying an estimated $38.9M and bringing the position to 1,393,027 shares worth $81M. The position accounts for 5.39% of the portfolio, ranked #5.

Caligan Partners first reported a position in XENE in Q3 2025 and has held it in 3 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Caligan Partners held 1,393,027 shares of Xenon Pharmaceuticals worth $81M as of Q1 2026.
  • Caligan Partners bought 843,362 Xenon Pharmaceuticals shares in Q1 2026, an estimated $38.9M.
  • Xenon Pharmaceuticals made up 5.39% of Caligan Partners's portfolio in Q1 2026, its #5 holding.
  • Caligan Partners first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.